
Tuesday, March 18, 2025

5:00 PM - 6:30 PM

PLENARY 1 - A Focus On Where We are At

- Opening remarks **John Ward and Norah Terrault**
- ISVHLD Remarks **Harry Janssen, Jordan Feld**
- Ray Schinazi & Stephan Urban Award Ceremony **John Ward, Norah Terrault, Harry Janssen, Jordan Feld, Ralf Bartenschlager**
- Bridging basic-clinical-implementation spheres in viral hepatitis + Q&A **Jordan Feld**
- Global progress on hepatitis B, C, and D elimination + Q&A **Meg Doherty**
- PANEL: Challenges on transitions of the US government and implications for hepatitis elimination in the US and global

Wednesday, March 19, 2025

8:30 AM - 10:00 AM

BASIC PARALLEL 1 - MishMASH: molecular mechanisms for liver disease

- MASH: molecular underpinnings of novel therapeutics **Percy Knolle**
- Lipoproteins and their role in hepatitis virus replication and liver disease **Ralf Bartenschlager**
- Oral Presentation
- Oral Presentation: A MOST RELEVANT MODEL OF HEPATITIS C VIRUS (HCV) INFECTION IN PRIMARY HUMAN HEPATOCYTES REVEALS THAT ALCOHOL INCREASES THE PRODUCTION OF BOTH VERY-LOW-DENSITY LIPOPROTEINS (VLDL) AND HIGHLY INFECTIOUS LIPO-VIRO-PARTICLES **Arielle Rosenberg**
- Oral Presentation: EVALUATION OF CELL FREE DNA METHYLATION AS LIQUID BIOPSY BIOMARKER TO DIFFERENTIATE HEPATITIS B VIRUS INDUCED HEPATOCELLULAR CARCINOMA FROM CHRONIC LIVER DISEASE **Baibaswata Nayak**
- Q&A

8:30 AM - 10:00 AM

CLINICAL PARALLEL 1 - Management of HBV in 2025

- Interferon as a Component of HBV Cure in 2024 and 2034 **Harry Janssen**
- Oral Presentation: IMMUNE SIGNATURE ASSOCIATED WITH VIRAL SUPPRESSION FOLLOWING NUCLEOS(T)IDE ANALOGUE TREATMENT IN ADULTS LIVING WITH CHRONIC HBV INFECTION IN SOUTH AFRICA **Marion Delphin**
- Oral Presentation
- Oral Presentation
- Oral Presentation
- Q&A

8:30 AM - 10:00 AM

CLINICAL PARALLEL 2 - Practical Strategies for implementing Guidelines and Maximizing Treatment Outcomes

- How to Engage and Support Priority Populations for Viral Hepatitis Care in Non-Endemic Regions **Christine Greenway**
- Development and Expansion of Novel Care Models for a Global Population

- Patient and Provider Perspective on Overcoming Barriers to Care **Su Wang**
- Oral Presentation: FACTORS INFLUENCING ANTIVIRAL MEDICATION ADHERENCE AMONG CHRONIC HEPATITIS B PATIENTS IN ADDIS ABABA: A MULTICENTER CROSS-SECTIONAL STUDY **Kaleb Berhane**
- Oral Presentation: DEVELOPMENT AND IMPLEMENTATION OF AN HEPATITIS D DETECTION AND LINKAGE TO CARE PROGRAM IN CATALONIA. PRELIMINARY RESULTS. **Maria Buti**
- Oral Presentation: WHAT DO WE KNOW ABOUT GENDER AND AGE IN GLOBAL HEPATITIS C TREATMENT WITH SOF/VEL? A STUDY OF 7,000 PATIENTS IN ASIA, LATIN AMERICA, MIDDLE EAST, NORDIC, AND SOUTHERN EUROPE **Fatima Higuera**
- Q&A

8:30 AM - 10:00 AM

PUBLIC HEALTH PARALLEL 0 - Oral Presentations:
Epidemiological Trends to Inform Policy Change

- Oral Presentation: PREVALENCE AND AWARENESS OF HEPATITIS B VIRUS INFECTION IN UZBEKISTAN — RESULTS FROM A POPULATION-BASED SEROSURVEY, 2022 **Nino Khetsuriani**
- Oral Presentation
- Oral Presentation: ESTIMATED NATIONAL HEPATITIS C PREVALENCE USING RESIDUAL SERA FROM A NATIONAL COMMERCIAL LABORATORY — UNITED STATES, NOVEMBER 2023–SEPTEMBER 2024 **Megan Hofmeister**
- Oral Presentation: PREVALENCE OF HEPATITIS B VIRUS INFECTION AND ASSOCIATED DEMOGRAPHIC, ECONOMIC AND BEHAVIORAL CHARACTERISTICS IN EIGHT SUB-SAHARAN AFRICAN COUNTRIES **Rania Tohme**
- Oral Presentation: PREVALENCE OF HBV AND HCV INFECTIONS AMONG AT-RISK MIGRANT AND REFUGEE POPULATIONS IN GREECE, ITALY AND SPAIN: 2-YEAR RESULTS OF THE VH-COMSAVAC PROJECT **Camila Picchio**
- Oral Presentation: PREVALENCE AND CORRELATES OF HEPATITIS C IN A MALAYSIAN PRISON **Mahija Ginjupalli**
- Q&A

8:30 AM - 10:00 AM	PUBLIC HEALTH PARALLEL 1 - Interventions to prevent viral hepatitis	<ul style="list-style-type: none"> • Prevention of hepatitis B and D (including PMTCT- increasing HBV birth dose, novel strategies to treat any woman HbsAg+ if no HBV DNA or birth dose available) Ben Cowie • Prevention of hepatitis C (focus on PWID – known interventions that are effective, such as opioid agonist treatment and syringe service programs) Julie Bruneau • Oral Presentation: MODELING THE EFFECT OF TARGETED INTERVENTIONS ON THE SPREAD OF HEPATITIS C THROUGH A NETWORK OF PEOPLE WHO INJECT DRUGS IN KENYA Ewan Colman • Oral Presentation • Oral Presentation: IMPACT OF A TREATMENT PEER-SUPPORT MODEL ON HEPATITIS B SCREENING AND LINKAGE TO INTEGRATED HIV/HBV CARE IN A HIGH BURDEN HBV SETTING IN NORTHERN UGANDA Joan J. Mutyoba • Oral Presentation: CHARACTERIZING ENGAGEMENT IN HEPATITIS C VIRUS TESTING AND CARE FOR INFANTS BORN TO PERSONS WHO TEST POSITIVE FOR HCV IN ONTARIO, CANADA Andrew B. Mendlowitz • Q&A
10:30 AM - 12:00 PM	PLENARY 2 - State of the Art: Report Card on Drug Development for HBV: Lessons Learned and the Path Forward	<ul style="list-style-type: none"> • Report Card on Drug Development for HBV: Lessons Learned and the Path Forward + Q&A Ed Gane • Oral Presentation: ANTI-HBSAG MONOCLONAL ANTIBODY BJT-778 DEMONSTRATES PANGENOTYPIC NEUTRALIZATION OF HEPATITIS B AND D VIRUSES + Q&A Ronald Alcalá • Oral Presentation: HBSAG LOSS IN INACTIVE CHRONIC HEPATITIS B CARRIERS IS DEPENDENT ON LEVEL OF QHBSAG AND INTERFERON RESPONSE: A RANDOMISED CONTROL TRIAL + Q&A Seng Gee Lim • Introductory Talk: Current & future therapies from a global perspective (challenges & barriers) Funmi Lesi • Panel - HBV Therapeutics (what's needed now and in the future) + Q&A
1:30 PM - 3:00 PM	CLINICAL PARALLEL 3 - ILCA-GHS HCC Symposium	<p>Moderator: Ju Dong Yang</p> <ul style="list-style-type: none"> • Risk stratification – HBV and post-SVR Nicole Kim • Debate – Are there patients that we can stop surveillance in low risk patients? Neil Mehta, Nicole Kim • Early detection/screening – surveillance underuse and emerging modalities Ju Dong Yang • Panel – implementation of these strategies Neil Mehta, Nicole Kim, Ju Dong Yang
1:30 PM - 3:00 PM	PUBLIC HEALTH PARALLEL 2 - Screening and diagnosis of viral hepatitis (Identifying the right test, for the right patient, in the right setting)	<ul style="list-style-type: none"> • Optimising strategies to enhance screening and diagnosis for hepatitis B Jean-Michel Pawlotsky • Optimising strategies to enhance screening and diagnosis for hepatitis C (lab-based testing, point-of-care testing, dried-blood spot testing, self-testing) Nathan Furukawa • Oral Presentation: EFFECTIVENESS OF HEALTH SYSTEM INTERVENTIONS ON UPTAKE OF HEPATITIS C SELF-TESTING (HCV-ST) IN URBAN SLUMS OF HARIDWAR: A PRAGMATIC CLUSTER RANDOMIZED CONTROL TRIAL Ajeet Singh

- Oral Presentation: LOW LEVELS OF VIRAL HEPATITIS AWARENESS, TESTING, AND HBV VACCINATION AMONG AT-RISK MIGRANT AND REFUGEE POPULATIONS IN GREECE, ITALY AND SPAIN: RESULTS FROM VH-COMSAVAC **Camilla Picchio**
- Oral Presentation: BENDING THE CURVE OF HEPATITIS C VIRUS INFECTION IN MACHAR COLONY: A MASS SCREEN AND TREAT INTERVENTION IN A SLUM SETTLEMENT IN KARACHI, PAKISTAN **Muhammad Khawar Aslam**
- Oral Presentation: PREP PROGRAMMES AS A FRAMEWORK FOR TACKLING HBV INFECTION IN ADOLESCENTS AND YOUNG ADULTS IN KWAZULU-NATAL, SOUTH AFRICA **Gloria Sukali**
- Q&A

3:30 PM - 5:00 PM

CLINICAL PARALLEL 4 - Optimizing HBV Treatment: Prospects for a functional cure

- Progress towards a Sterilizing Cure - Advances in Gene editing and Targeting cccDNA **Fabien Zoulim**
- The Role of RNA interference (siRNA, ASO) as the backbone of HBV Cure strategies **Kosh Agarwal**
- Therapeutic Vaccines and Other Immune Targets for Functional Cure, How Good is the Promise? **Adam Gehring**
- Oral Presentation: ASSOCIATION OF HEPATITIS B SURFACE ANTIGEN LOSS WITH CLINICAL OUTCOMES AMONG PATIENTS WITH CHRONIC HEPATITIS B INFECTION: A RETROSPECTIVE COHORT STUDY IN THE UNITED STATES **Anna Coutinho**
- Oral Presentation: TREATMENT RELATED NORMALIZATION OF ALT IS ASSOCIATED WITH RESOLUTION OF SIGNIFICANT LIVER INFLAMMATION IN PATIENTS WITH CHRONIC HEPATITIS B **Lisa van Velsen**
- Q&A

3:30 PM - 5:00 PM

CLINICAL PARALLEL 5 - Delta Therapies - Current and Future

- Overview of New Drug Development for Hepatitis Delta **Pietro Lampertico**
- Bulevirtide (BLV) as Monotherapy or Combination Treatment with Interferon for Hepatitis Delta **Maria Buti**
- Management of Delta for indigenous populations **Thor Dantas**
- Oral Presentation: EFFICACY AND SAFETY OF BLV MONOTHERAPY FOR CHRONIC HEPATITIS DELTA: POSTTREATMENT RESULTS THROUGH 48 WEEKS AFTER THE END OF TREATMENT FROM AN INTERIM ANALYSIS OF A RANDOMIZED PHASE 3 STUDY MYR301 **Pietro Lampertico**
- Oral Presentation: SAFETY AND EFFICACY OF REP 2139-MG IN HEPATITIS D PATIENTS: REPORTING OF EXTENDED FOLLOW-UP DATA FROM THE INTERNATIONAL COMPASSIONATE USE PROGRAM **Christiane Stern**
- Q&A

3:30 PM - 5:00 PM

PUBLIC HEALTH PARALLEL 3 - Interventions to enhance testing, treatment, and viral elimination

- Interventions to enhance linkage to hepatitis C care and treatment (not diagnostic strategies - e.g. electronic medical record audit, financial incentives, peer support, pharmacy starter packs) **Seun Falade-Nwulia**
- Interventions to enhance linkage to hepatitis B & D care and treatment (not diagnostic strategies) **Alexander Stockdale**
- Oral Presentation: LINKAGE TO CARE OF PEOPLE WHO INJECT DRUGS WITHIN NATIONAL HEPATITIS C ELIMINATION PROGRAM IN GEORGIA **Maka Gogia**

- Oral Presentation: EVALUATING THE IMPACT OF INCREASED PROVISION OF LOW DEAD SPACE SYRINGES ON HIV AND HCV TRANSMISSION AMONG PEOPLE WHO INJECT DRUGS: A MODELLING ANALYSIS FOR 19 COUNTRIES **Peter Vickerman**
- Oral Presentation: OPTIMIZING HEALTHCARE SYSTEMS FOR VIRAL HEPATITIS ELIMINATION: AUTOMATING EMR-BASED HEPATITIS B AND C SCREENING **Su Wang**
- Oral Presentation: ACHIEVEMENTS AND CHALLENGES IN SCALING HCV SERVICES TO PRIMARY HEALTHCARE (PHC) FACILITIES IN CAMBODIA **Alethea Tan**
- Q&A

Thursday, March 20, 2025

8:30 AM - 10:00 AM	BASIC PARALLEL 2 - Dueling virology: HBV and HDV	<ul style="list-style-type: none"> • Molecular basis for an HBV cure using antivirals Chloe Thio • From controlling HDV to HDV cure Marc Ghany • Oral Presentation: A NOVEL LONG-ACTING HBV/HDV ENTRY INHIBITOR Jimmy Zhang • Oral Presentation • Oral Presentation • Q&A
8:30 AM - 10:00 AM	CLINICAL PARALLEL 6 - HBV Treatment Challenges and Controversies	<ul style="list-style-type: none"> • Debate: Do Not Stop Long-Term NA Therapy in Absence of Functional Cure (against) Anna Lok • Debate: You Can Stop Long-Term Therapy in Absence of Functional Cure (for) Rachel Jeng • What is the Evidence for Expanding NA Therapy Patrick Kennedy • Oral Presentation: EARLY OFF-TREATMENT HBCRAG AND ANTI-HBC LEVELS IDENTIFY PATIENTS AT HIGH RISK OF SEVERE ALT FLARES AFTER NUCLEOS(T)IDE ANALOGUE WITHDRAWAL – A POOLED ANALYSIS OF TWO PROSPECTIVE STUDIES Edo Dongelmans • Oral Presentation: HEPATOCELLULAR CARCINOMA RISK IN HISPANICS WITH CHRONIC HEPATITIS B Ariel Lee • Oral Presentation: HBV-HIV CO-INFECTION & TENOFOVIR INTERRUPTION IN THE UNITED STATES: MONITORING PRACTICES AND INCIDENCE OF HEPATITIS B REACTIVATION OR HEPATITIS FLARE Douglas T. Dieterich • Q&A
8:30 AM - 10:00 AM	PUBLIC HEALTH PARALLEL 4 - Special Populations	<ul style="list-style-type: none"> • Corrections/Jails Nadine Kronfli • Addressing Challenges to Engage People who Use Drugs into Care - A Community Perspective Sione Crawford • Overseas born/refugees/migrants - Overview Nasra Giama • Collaborating with First Nations Communities to Enhance Hepatitis C Care Kate Dunn • Q&A
10:30 AM - 12:00 PM	PLENARY 3 - State of the Art: Thinking outside the Box for HCV: Treat to Cure and Eliminate	<ul style="list-style-type: none"> • Thinking outside the Box for HCV: Treat to Cure and Eliminate + Q&A Margaret Hellard • Oral Presentation: NEW HIV, HCV AND HBV INFECTIONS ATTRIBUTED TO UNSAFE MEDICAL INJECTIONS IN LOW AND MIDDLE-INCOME

COUNTRIES: AN ANALYSIS BASED ON DEMOGRAPHIC AND HEALTH SURVEYS + Q&A **Adelina Artenie**

- Oral Presentation + Q&A
- Pharmacology of long-acting HCV therapeutics **Andrew Owen**
- Panel + Q&A

1:30 PM - 3:00 PM

BASIC PARALLEL 3 - Exploiting adaptive immunity to combat viral hepatitis

- Restoring immunity to cure hepatitis B **Ulrike Protzer**
Immunologic prescription for a vaccine to prevent chronic hepatitis C **Andrea Cox**
- Oral Presentation: MYELOID CELLS SUPPORT THE INDUCTION OF AUTO-AGGRESSIVE CD8 T CELLS IN CHRONIC HEPATITIS B **Wei Ting (Jonah) Lin**
- Oral Presentation: RNAI SYNERGIED WITH PEGIFN α IN CHRONIC HEPATITIS B TREATMENT VIA AUGMENTED EPIGENETIC REPRESSION OF CCCDNA AND ALTERED T/B CELL CROSSTALK **Zhenghon Yuan**
- Oral Presentation
- Q&A

1:30 PM - 3:00 PM

CLINICAL PARALLEL 7 - New Diagnostics and Technologies in Liver Disease - Potential for Current and Future Clinical Practice

- Novel Biomarkers and Point of Care Tests for HBV management **Lung Yi Mak**
- Application of Artificial Intelligence in Viral Hepatitis **Terry Yip**
- Oral Presentation: PERFORMANCE OF ELECSYS ANTI-HEV IGG AND IGM ASSAYS FOR THE DETECTION OF ACUTE, RECENT, OR PAST HEPATITIS E VIRUS INFECTION **Korbinian Kienle**
- Oral Presentation: REAL-WORLD IMPLEMENTATION OF POINT-OF-CARE (POC) HCV RNA TESTING IN A MOBILE UNIT IN HOMELESS ENCAMPMENTS AND SHELTERS IN ONTARIO, CANADA: IMPACT ON THE CASCADE OF CARE **Lindsay Myles**
- Oral Presentation: NON-INVASIVE METHODS FOR DIAGNOSING PORTAL HYPERTENSION AND VARICEAL BLEEDING DUE TO LIVER CIRRHOSIS SECONDARY TO NAFLD **Nebyu Yonas Shanku**
- Q&A

1:30 PM - 3:00 PM

PUBLIC HEALTH PARALLEL 5 - Hepatitis B, C, D elimination

- Novel Interventions to Facilitate Hep C Elimination in Rural Settings (Integrating work on larger scale, randomized control trials, rural home test kits) **Jennifer Havens**
 - Addressing Barriers to Hepatitis B Screening in Low and Middle Income Settings **Tanwadee Tawasek**
 - Oral Presentation: MODELING HEPATITIS C VIRUS ELIMINATION IN THE UNITED STATES: ARE WE ON TRACK TO REACH INCIDENCE TARGETS? **Natasha Martin**
PROGRESS TOWARD HEPATITIS C ELIMINATION IN HIGH-INCOME COUNTRIES **Homie Razavi**
 - Oral Presentation: A COMPARATIVE ANALYSIS OF NATIONAL HBV ELIMINATION POLICIES, PROGRAMS, AND PROGRESS ACROSS INCOME LEVELS **Jana Manning**
 - Oral Presentation: MODELLING THE IMPACT AND COST-EFFECTIVENESS OF SCALING UP OF HCV CASE FINDING AND TREATMENT FOR ACHIEVING ELIMINATION AMONG PEOPLE WHO INJECT DRUGS IN ENGLAND **Peter Vickerman**
 - Q&A
-

3:30 PM - 5:00 PM	CLINICAL PARALLEL 8 - Overlapping Epidemics: Viral Hepatitis Meets Steatotic Liver Disease	<ul style="list-style-type: none"> Alcohol and Viral Hepatitis: How Much is too Much? Jennifer Flemming Risk of HCC in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) and Viral Hepatitis Mindie Nguyen Oral Presentation Oral Presentation: LOW VIRAL LOAD ASSOCIATED WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AMONG PEOPLE LIVING WITH HEPATITIS B VIRUS (PLWHB) IN A DIVERSE CENTRAL LONDON CLINIC Emily Martyn Oral Presentation Q&A
3:30 PM - 5:30 PM	CLINICAL PARALLEL 9 - Remaining Challenges in Hepatitis C	<ul style="list-style-type: none"> HCV : Improving care after HCV diagnosis and after HCV Cure Jennifer Price Treatment of HCV in Context of HCC - Remaining Challenges in 2025 George Ioannou Oral Presentation: A NATIONAL PROGRAM TO SCALE-UP POINT-OF-CARE TESTING AND TREATMENT FOR HEPATITIS C INFECTION IN AUSTRALIA, 2022-2024 Jason Grebely Oral Presentation: HOW MUCH DAA TREATMENT IS ENOUGH? OUTCOMES FROM A LARGE CASE SERIES OF HCV TREATMENT INTERRUPTIONS Astha Kanani Oral Presentation Q&A
3:30 PM - 5:00 PM	PUBLIC HEALTH PARALLEL 6 - Pathways towards Hepatitis Elimination	<ul style="list-style-type: none"> WHO Progress, and Next Steps toward hepatitis elimination Funmi Lesi Spain Javier Garcia-Samaniego South Korea Su Jong Yoo Pakistan Saeed Hamid Plans, policies and progress toward hepatitis elimination: Findings from 33 national profiles Lindsey Hiebert Q&A
Friday, March 21, 2025		
8:30 AM - 10:00 AM	BASIC PARALLEL 4 - Gene- and Cell therapies - latest news	<ul style="list-style-type: none"> CAR-T cells in liver transplantation Elmar Jaeckel Gene correction in the liver using CRISPR Alexander Ploss CRMA-1001 AN EPIGENETIC EDITOR FOR THE TREATMENT OF CHRONIC HEPATITIS B Yesseinia Anglero-Rodriguez PBGENE-HBV DEFINITIVE PRECLINICAL TOXICOKINETIC AND TOXICOLOGY DATA ENABLES ADVANCEMENT TO CLINICAL TRIALS FOR A POTENTIALLY CURATIVE GENE EDITING TREATMENT FOR CHRONIC HEPATITIS B Andrew Van Cott INHIBITING HDV BY ADENINE BASE EDITING OF HEPATITIS B SURFACE ANTIGEN Anuj Kumar Q&A
8:30 AM - 10:00 AM	CLINICAL PARALLEL 10 - Special Populations in Viral Hepatitis	<ul style="list-style-type: none"> Immunocompromised Patients and Viral Hepatitis Management Karen Doucette Management of Children with Viral Hepatitis (i.e., Immuntolerant or High Replicative, Non-Inflammatory) Ravi Jahvari

- Oral Presentation: HEPATITIS B REACTIVATION AND TRANSMISSION OUTCOMES IN KIDNEY TRANSPLANTATION: A RETROSPECTIVE COHORT STUDY **Imran Hasanoglu**
- Oral Presentation
- Oral Presentation
- Q&A

8:30 AM - 10:00 AM

PUBLIC HEALTH PARALLEL 7 - Panel Discussion:
Innovations to Accelerate Hepatitis Elimination

Moderator: **Jason Grebely**

- The Role of Policy Development in the Access to New Prevention Screening & Treatment **Carolyn Wester**
- How to Implement New Diagnostic Technologies in the Field **Boatema Ntiri-Reid**
- Access to the Latest Therapies **Mila Maistat**
- The Roles of Communities of Practice: To Implement New Technologies & Strategies **Sanjeev Arora**
- Panel Discussion + Q&A

10:30 AM - 12:00 PM

PLENARY 4 - State of the Art: Towards Achieving
Health Equity

Moderator: **John Ward**

- Australia **Greg Dore**
- UK **David Leeman**
- Spain **Camila Picchio**
- Africa **Ponsianoo Ocama**
- Morocco
- China **Cui Fuqiang**
- Panel + Q&A